Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 4, Issue 11, 2009, Pages 1389-1396

  Sequist, Lecia V ^a   Fidias, Panos M ^a   Temel, Jennifer S ^a   Kolevska, Tatjana ^b   Rabin, Michael S ^c   Boccia, Ralph V ^d   Burris, Howard A ^e   Belt, Robert J ^f   Huberman, Mark S ^g   Melnyk, Ostap ^h   Mills, Glenn M ⁱ   Englund, Craig W ^j   Caldwell, David C ^k   Keck, James G ^l   Meng, Lisa ^l   Jones, Marsha ^l   Brown, Gail L ^l   Edelman, Martin J ^m   Lynch, Thomas J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b KAISER PERMANENTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d Center for Cancer and Blood Disorders   (United States)

^e SARAH CANNON RESEARCH INSTITUTE   (United States)

^f Kansas City Cancer Center   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h Bay Area Cancer Research Group LLC   (United States)

ⁱ LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^j Florida Well Care   (United States)

^k Danville Hematology Oncology   (United States)

^l Telik Inc   (United States)

^m UNIVERSITY OF MARYLAND   (United States)

more..

Author keywords

Canfosfamide; Carboplatin; NSCLC; Paclitaxel; Phase 2

Indexed keywords

CANFOSFAMIDE; CARBOPLATIN; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OBSTRUCTIVE JAUNDICE; PANCYTOPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SEPSIS; SURVIVAL TIME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TYPHLITIS; VOMITING;

EID: 70449623325     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181b6b84b     Document Type: Article

References (39)

1. American Cancer Society Cancer Facts & Figures 2009. Available at: http://www.cancer.org/docroot/STT/content/STT-1x-Cancer-Facts- Figures-2009.asp?from-fast. 2009. Accessed February 15, 2009.
2. Schiller JH, Harrington D, Belani CP, et al. Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
3. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 2542-2550. (Pubitemid 44917502)
5. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003;22:7369-7375.
6. O'Brien ML, Tew KD. Glutathione and related enzymes in multidrug resistance. Eur J Cancer 1996;32A:967-978.
7. Eimoto H, Tsutsumi M, Nakajima A, et al. Expression of the glutathione S-transferase placental form in human lung carcinomas. Carcinogenesis 1988;9:2325-2327.
8. Inoue T, Ishida T, Sugio K, Maehara Y, Sugimachi K. Glutathione S transferase Pi is a powerful indicator in chemotherapy of human lung squamous-cell carcinoma. Respiration 1995;62:223-227.
9. Miyazaki M, Kohno K, Saburi Y, et al. Drug resistance to cis-diamminedichloroplatinum (II) in Chinese hamster ovary cell lines transfected with glutathione S-transferase pi gene. Biochem Biophys Res Commun 1990;166:1358-1364.
10. McIlwain CC, Townsend DM, Tew KD. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 2006;25:1639-1648.
11. Gate L, Tew KD. Glutathione S-transferases as emerging therapeutic targets. Expert Opin Ther Targets 2001;5:477-489.
12. Xu H, Meng S, Laborde E, et al. TLK286-induced activation of the stress response apoptotic signaling pathway. In Proceedings of the Annual Meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, 2003. p. 604.
13. Rosen LS, Brown J, Laxa B, et al. Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res 2003;9:1628-1638.
14. Xu H, Namgoong S, Roth E, et al. Synergistic effect of TELCYTA™ (TLK286) in combination with paclitaxel, doxorubicin, carboplatin, oxaliplatin, cisplatin, docetaxel, gemcitabine and iressa in human cancer cells. In Proceedings of the Annual Meeting of the American Association for Cancer Research, Orlando, FL, 2004. p. 462.
15. Wang Z, Keck JG, Brown GL, et al. TLK286, a novel glutathione analog prodrug, induces resensitization to carboplatin in human ovarian cancer, OVCAR3, platinum resistant cells. In Proceedings of the Annual Meet- ing for the American Association for Cancer Research, Anaheim, CA, 2005. Pp. 351-352.
16. Rosen LS, Laxa B, Boulos L, et al. Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res 2004; 10:3689-3698.
17. Kavanagh JJ, Gershenson DM, Choi H, et al. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005;15:593-600.
18. Xu H, Namgoong S, Roth E, et al. Synergistic cancer cell cytotoxicity of TLK286 (Telcyta) in combination with carboplatin, cisplatin, doxorubicin, docetaxel, paclitaxel or oxaliplatin in human ovarian, lung, breast and colorectal cancer cell lines. In Proceedings of the American Association for Cancer Research, Washington, DC, 2003. Abstract no. C156.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
20. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
21. Freidlin B, Breathnach OS, Johnson BE. A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Clin Cancer Res 2003;9:917-922.
22. NCI: National Cancer Institute Common Toxicity Criteria (CTC), DCTD, NCI, NIH, DHHS, April 30, 1999.
23. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784. (Pubitemid 41103588)
24. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794. (Pubitemid 41103589)
25. Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol. 2007;25:1545-1552.
26. Herbst RS, Prager D, Hermann R, et al. TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced nonsmall- cell lung cancer. J Clin Oncol 2005;23:5892-5899.
27. Bissett D, O'Byrne KJ, von Pawel J, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005;23:842-849.
28. Ramlau R, Zatloukal P, Jassem J, et al. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/ vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. J Clin Oncol 2008;26:1886 -1892.
29. Blumenschein GR Jr, Khuri FR, von Pawel J, et al. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. J Clin Oncol 2008;26:1879-1885.
30. Lynch TJ, Raju R, Lind M, et al. Randomized phase III trial of chemotherapy and antisense oligonucleotide LY900003 (ISIS 3521) in patients with advanced NSCLC: Initial report. In Proceedings of the Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, 2003. p. 623.
31. Williamson SK, Crowley JJ, Lara PN Jr, et al. Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-smallcell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol 2005;23:9097-9104.
32. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an openlabel randomised phase III trial. Lancet 2009;373:1525-1531.
33. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
34. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-smallcell lung cancer. Ann Oncol 2008;19:362-369.
35. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
36. Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). American Society of Clinical Oncology. Chicago, IL. J Clin Oncol 2008;26 (abstract LBA8012).
37. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: a randomized phase III study in advanced non-small cell lung cancer (NSCLC). American Society of Clinical Oncology. Orlando, FL. J Clin Oncol 2009;27 (abstract CRA8000).
38. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. American Society of Clinical Oncology. Orlando, FL. J Clin Oncol 2009;27 (abstract 8001).
39. Miller V, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). American Society of Clinical Oncology. Orlando, FL. J Clin Oncol 2009;27 (abstract LBA8002).